A growing volume of preclinical data linking dysbiosis to unfavorable solid organ transplant outcomes such as graft rejection is fueling calls for more rigorous research.
JP Morgan Healthcare Conference, Day 1: Oxford Nanopore, 10x Genomics, Bruker, Qiagen, More
Highlights from the first day included Exact Sciences' plan to launch three new cancer tests in 2025 and Qiagen's sample prep launch plans for 2026.
JP Morgan Healthcare Conference, Day 2: CareDx, Thermo Fisher, BillionToOne, Adaptive Biotech, More
Highlights from the second day included BillionToOne's 2024 revenue spike and CareDx's plan to expand indications for its transplant tests.
JP Morgan Healthcare Conference, Day 4: Standard BioTools, Geneoscopy, OraSure Technologies
Highlights from the fourth day included Geneoscopy's plans to increase access to its ColoSense colorectal cancer screening test through its partnership with Labcorp.
The molecular test is used to differentiate bacterial infections, viral infections, and noninfectious disease and to assess the risk that patients will develop severe illness.
The retrospective results suggest that the test's sensitivity boost over other platforms can overcome the challenge of detecting ctDNA in adenocarcinomas.
Through close collaboration of more than 300 genomics and disease experts, the pan-European consortium solved more than 500 difficult cases.
JP Morgan Healthcare Conference, Day 3: Grail, Ultima Genomics, Seer, GeneDx, Quanterix
Highlights from the third day included Quanterix's announcement of a new protein detection platform, to be launched later this year.